Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000: 1)
The bill (REMEDY Act) amends the Federal Food, Drug, and Cosmetic Act (section 505) to change how patents are handled when an applicant seeks approval of an abbreviated new drug application (ANDA). For drugs approved on or after enactment, the holder who first files patent information under 505(c)(2) must select one patent (a “covered patent”) from among the patents described in the statute; that selection is binding and cannot be changed.
Progressives emphasize consumer benefits from faster generic entry and reduced ‘evergreening’; conservatives emphasize protection of IP rights and incentives for pharmaceutical R&D.
Relative to its intended legislative type, this bill is a targeted substantive amendment to the Federal Food, Drug, and Cosmetic Act that prescribes specific procedural changes to abbreviated new drug application patent‑listing and thirty‑month stay rules by introducing a non‑modifiable 'covered patent' selection and adjusting trigger language in subsections (c) and (j).
The bill (REMEDY Act) amends the Federal Food, Drug, and Cosmetic Act (section 505) to change how patents are handled when an applicant seeks approval of an abbreviated new drug application (ANDA).
For drugs approved on or after enactment, the holder who first files patent information under 505(c)(2) must select one patent (a “covered patent”) from among the patents described in the statute; that selection is binding and cannot be changed.
The amendments narrow which patents can trigger the statutory 30‑month stay of ANDA approval (the stay applies to the selected covered patent for post‑enactment approvals) and make parallel edits in both the 505(c) and 505(j) provisions to reflect the single‑patent selection and related timing rules.
The bill is a targeted, legally technical reform with clear policy beneficiaries and opponents. Because it does not create new spending or large administrative programs it avoids some obstacles, but it directly affects a powerful industry (innovator pharmaceutical firms) and interacts with complex patent and litigation incentives. Those factors, combined with the lack of compromise mechanisms in the text, make enactment plausible but uncertain absent significant stakeholder negotiation and amendment.
Relative to its intended legislative type, this bill is a targeted substantive amendment to the Federal Food, Drug, and Cosmetic Act that prescribes specific procedural changes to abbreviated new drug application patent‑listing and thirty‑month stay rules by introducing a non‑modifiable 'covered patent' selection and adjusting trigger language in subsections (c) and (j). The draft is precise in the statutory text it changes but lacks an explicit purpose statement, fiscal or resourcing discussion, and detailed treatments of several implementation contingencies.
Progressives emphasize consumer benefits from faster generic entry and reduced ‘evergreening’; conservatives emphasize protection of IP rights and incentives for pharmaceutical R&D.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize consumer benefits from faster generic entry and reduced ‘evergreening’; conservatives emphasize protection of IP rights and incentives for pharmaceutical R&D.
A mainstream progressive would likely view the bill positively as a targeted fix to ‘evergreening’ tactics that can delay generic competition.
They would read the single covered‑patent rule as a concrete mechanism to reduce serial patent listings and artificial extensions of exclusivity, which can keep prices high.
They would see this as a pro‑consumer, pro‑competition reform while noting it is limited to drugs approved on or after enactment.
A moderate would generally view the bill as a technical, narrowly focused reform to reduce a particular type of strategic behavior that delays competition.
They would appreciate the attempt to balance generics access with patent rights, but would want clarity on transitional rules, legal defensibility, and unintended consequences for innovation.
Overall, a centrist would be cautiously supportive provided the bill is implemented with clear definitions, monitoring, and possibly a review/adjustment mechanism after a trial period.
A mainstream conservative would likely be skeptical of the bill because it narrows patent enforcement tools and constrains how patent owners can protect their property.
They would view the single‑patent selection and binding limitation as an erosion of intellectual property rights that could weaken incentives for pharmaceutical R&D.
While they might acknowledge the policy goal of faster generics, they would be concerned about government micromanagement of patent enforcement and potential negative effects on investment and innovation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
The bill is a targeted, legally technical reform with clear policy beneficiaries and opponents. Because it does not create new spending or large administrative programs it avoids some obstacles, but it directly affects a powerful industry (innovator pharmaceutical firms) and interacts with complex patent and litigation incentives. Those factors, combined with the lack of compromise mechanisms in the text, make enactment plausible but uncertain absent significant stakeholder negotiation and amendment.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize consumer benefits from faster generic entry and reduced ‘evergreening’; conservatives emphasize protection of IP rig…
The bill is a targeted, legally technical reform with clear policy beneficiaries and opponents. Because it does not create new spending or…
Relative to its intended legislative type, this bill is a targeted substantive amendment to the Federal Food, Drug, and Cosmetic Act that prescribes specific procedural changes to abbreviated new drug application patent…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.